Liang Yutang, president of Jinling Pharmaceutical, resigned Chen Yajun took over

On December 11, 2020, Jinling Pharmaceutical (000919) recently held the fourth meeting of the eighth board of directors on December 11, 2020, and deliberated and passed the "Proposal on Adjusting the Positions of senior management personnel of the Company and Hiring the President of the Company". According to the needs of the company's development and production and operation work, after the deliberation and approval of the company's board of directors, it was agreed to adjust the position of president of Liang Yutang, and Liang Yutang no longer served as the president of the company from the date of the fourth meeting of the eighth board of directors, and Liang Yutang continued to serve as the chairman of the board of directors of the company after leaving office.

The Board of Directors of the Company agreed to appoint Chen Yajun as the President of the Company for a term of office from the date of adoption at the fourth meeting of the Eighth Board of Directors to the expiration of the term of office of the current Board of Directors.

As of the date of this announcement, Liang Yutang holds 137,810 shares of the company's shares, and the shares of the company he holds will be managed in accordance with the rules for the listing of shares on the Shenzhen Stock Exchange and several provisions on the reduction of shares by shareholders and directors and supervisors of listed companies.

According to the data of the digging shell network, the main business of Jinling Pharmaceutical is pharmaceutical manufacturing and medical and health care services.

Source link: http://www.cninfo.com.cn/new/disclosure/detail?plate=szse&orgid=gssz0000919&stockcode=000919&announcementid=1208892507&announcementtime=2020-12-12

This article originated from the digging shell network